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Abstract
Background: Primary postpartum haemorrhage is an obstetrical emergency often causing acute anaemia that may
require immediate red blood cell (RBC) transfusion. This anaemia results in symptoms such as fatigue, which may
have major impact on the health-related quality of life. RBC transfusion is generally thought to alleviate these
undesirable effects although it may cause transfusion reactions. Moreover, the postpartum haemoglobin level
seems to influence fatigue only for a short period of time. At present, there are no strict transfusion criteria for this
specific indication, resulting in a wide variation in postpartum policy of RBC transfusion in the Netherlands.
Methods/Design: The WOMB trial is a multicentre randomised non-inferiority trial. Women with acute anaemia
due to postpartum haemorrhage, 12-24 hours after delivery and not initially treated with RBC transfusion, are
eligible for randomisation. Patients with severe physical complaints are excluded. Patients are randomised for either
RBC transfusion or expectant management. Health related quality of life (HRQoL) will be assessed at inclusion, at
three days and one, three and six weeks postpartum with three validated measures (Multi-dimensional Fatigue
Inventory, ShortForm-36, EuroQol-5D). Primary outcome of the study is physical fatigue three days postpartum.
Secondary outcome measures are general and mental fatigue scores and generic health related quality of life
scores, the number of RBC transfusions, length of hospital stay, complications and health-care costs.
The primary analysis will be by intention-to-treat. The various longitudinal scores will be evaluated using Repeated
Measurements ANOVA. A costs benefit analysis will also be performed. The power calculation is based on the
exclusion of a difference in means of 1.3 points or greater in favour of RBC transfusion arm regarding physical
fatigue subscale. With missing data not exceeding 20%, 250 patients per arm have to be randomised (one-sided
alpha = 0.025, power = 80%).
Discussion: This study will provide evidence for a guideline regarding RBC transfusion in the postpartum patient
suffering from acute anaemia. Equivalence in fatigue score, remaining HRQoL scores and physical complications
between both groups is assumed, in which case an expectant management would be preferred to minimise
transfusion reactions and costs.
Trial registration: ClinicalTrials.gov NCT00335023, Nederlands Trial Register NTR335.
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One of the most frequent complications of delivery is
primary postpartum haemorrhage (PPH), defined as
blood loss greater than or equal to 500 ml within
24 hours after birth and severe PPH as blood loss
greater than or equal to 1000 ml within 24 hours [1].
Between four and five percent of all vaginal deliveries
are complicated by severe PPH [2]. Blood loss during
caesarean section is usually 50-100% more than during
vaginal delivery [3]. An important clinical effect of
obstetric haemorrhage is the development of acute anae-
mia, with fatigue as an important symptom. This fatigue
is not an isolated physical symptom but rather involves
lethargy, decreased mental alertness, physical weakness
and poor concentration [4]. It is especially important as
it affects women who just have delivered, who have to
care for and feed a newborn baby and who are usually
full of emotions.
RBC transfusion is one of the few treatments that ade-
quately restore tissue oxygenation when oxygen demand
exceeds supply. Apart from the life-saving restoration of
the initial hemodynamic instability, RBC transfusion is
also used to alleviate the side-effects of acute anaemia,
including the fatigue mentioned above. This treatment
is applied frequently. Previously, a significant correlation
between Hb level postpartum and fatigue scores was
found in postpartum patients using the HRQoL measure
Multidimensional Fatigue Inventory (MFI), but this cor-
relation was already lost one week after delivery [5].
Thus, postpartum haemoglobin (Hb) level seems to
influence fatigue for only a short period of time. Other
arguments against RBC transfusion are that RBC trans-
fusion is costly and may cause formation of RBC alloan-
tibodies and other direct and indirect transfusion
complications [6].
Although the respiratory function of blood has been
studied intensively, the trigger for RBC transfusion
remains controversial, and doctors still rely primarily on
clinical experience. At present, criteria for transfusion
are not based on alternative criteria, such as HRQoL
scores. Worldwide there is no consensus on the optimal
transfusion trigger [6-9]. A questionnaire study in 2003
on the subject of RBC transfusion practice postpartum
in the Netherlands also showed large differences
between hospitals [10]. Based on Hb levels, the transfu-
sion triggers varied between 3.0 and 5.5 mmol/L (4.8
and 8.9 g/dL). Clinical symptoms were used as more or
less subjective additional criteria.
The official Dutch guideline for RBC transfusion is the
“4-5-6 flexinorm” for patients with acute or chronic
anaemia [9]. This rule states that ASA I patients should
have RBC transfusion when their Hb is below 4 mmol/L
(6.4 g/dL), ASA II when their Hb is below 5 mmol/L
(8.1 g/dL) and ASA III and IV patients when their Hb is
below 6 mmol/L (9.7 g/dL). However, during pregnancy
the circulating blood volume increases by 100 mL/kg to
a total blood volume of six to seven liters. The several
blood components contribute differently to this increase:
plasma increases with 40% whereas red blood cell
volume increases with 15-20%. Consequently Hb level
decreases with a maximum of approximately 10%. This
natural process of hemodilution improves the placental
circulation. As a result of these changes, it is doubtful
w h e t h e rt h eH bt r i g g e r sf o rR B Ct r a n s f u s i o n ,a s
described above, can be used for patients with postpar-
tum haemorrhage.
In the Netherlands all women with PPH will be trea-
ted by a gynaecologist in a clinical setting. Although
almost one third of Dutch women deliver at home with
supervision by a midwife, women that experience exces-
sive blood loss during or immediately after delivery will
be transferred to a hospital for further treatment by a
gynaecologist. Most Dutch women that have a hospital
delivery, leave hospital a couple of hours after delivery
since there is an adequately organised domiciliary post-
natal care service. The necessity of RBC transfusion will
prolong their stay in hospital.
In the Netherlands, blood products are produced by
one blood banking organisation. The present study is
performed in cooperation with Sanquin, the Dutch
blood bank organisation, which initiated and funded the
costs of the first part of this study.
Acute anaemia postpartum, with fatigue as important
symptom, is a clinical problem with wide practice varia-
tion in treatment regarding RBC transfusion. There are
several arguments against RBC transfusion and the post-
partum Hb level seems to influence fatigue for only a
short period of time. We therefore aim to show non-
inferiority of expectant management versus a transfusion
policy regarding physical fatigue, three days after deliv-
ery, in postpartum women with an acute anaemia fol-
lowing PPH. The development of a guideline based on
clinical parameters, laboratory determinations and
HRQoL measures may lead to a more adequate use of
RBC transfusions in the postpartum period and possibly
reduces costs due to lower frequency of transfusions
and hospitalization duration.
Methods/design
Aims
T h ea i mo ft h i ss t u d yi st os o l v et h ed i l e m m af o rt h e
obstetrician regarding the optimal treatment of women
with acute anaemia postpartum. For that reason we
determine whether women with acute anaemia postpar-
tum benefit from RBC transfusion.
Our hypothesis is that there is no important difference
with regard to physical fatigue, as well as other HRQoL
scores and physical complications between RBC
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women with acute postpartum anaemia in the absence
of (severe) physical complaints.
If this hypothesis is true, an expectant management is
to be preferred to minimise transfusion related reactions
and costs.
Study design
The study is a multicentre randomised non-inferiority
trial in women with an acute postpartum anaemia. It is
an open label study. This trial is embedded in the Dutch
Obstetric Consortium, a collaboration of hospitals in the
Netherlands [11]. Approximately 40 hospitals, including
university hospitals, teaching hospitals and non-teaching
hospitals will participate in this trial.
Participants/eligibility criteria
Women, older than 18 years of age, who deliver in hospital
or are transferred after home delivery because of PPH, are
eligible. Patients will be included with an Hb between 3.0
and 5.0 mmol/L (4.8 and 8.1 g/dL), determined 12 to
24 hours after vaginal delivery or caesarean section, and a
decrease in Hb of at least 1.2 mmol/L (1.9 g/dL) and/or a
total peripartum blood loss of at least 1000 mL. The initial
Hb value will be determined when the patient is admitted
during the first stage of labour at the labour ward. In other
instances, when an initial Hb is absent, inclusion is purely
based on the total amount of blood loss. Exclusion criteria
include severe (anaemic) physical complaints, previous
RBC transfusion directly after delivery, severe pre-eclamp-
sia, severely active infectious disease, congenital haemoly-
tic disease, severe compromised immunological status,
malignancy, severe co-morbidity (ASA II/III), peripartum
death or critical condition of the newborn. Severe (anae-
mic) physical complaints were defined as fatigue, head-
ache, dizziness, confusion, dyspnoea, syncope, orthostatic
complaints, tachycardia (> 100 bpm), angina pectoris and/
or transient ischemic attacks (TIA). Finally, good working
knowledge of the Dutch language is required.
Procedures, recruitment, randomisation and collection of
baseline data
Eligible patients receive participant information. After
written consent, participants are randomised by means
of a web-based application [12]. Randomisation will be
blocked in a 1:1 ratio for RBC transfusion or expectant
management. Stratification will be applied for mode of
delivery and participating hospital.
All data will be collected, coded and processed with
adequate precautions to ensure patient confidentiality.
Intervention and control
RBC transfusion will be compared with expectant
management.
In patients allocated to RBC transfusion, at least one
unit of packed cells will be given. The desired Hb level
after transfusion is 5.5 mmol/L (8.9 g/dL). The units of
blood will be matched, pre-treated and tested according
to the Dutch guidelines for RBC transfusion. Before and
15-90 minutes after transfusion maternal body tempera-
ture, blood pressure and heart rate will be checked and
a blood sample is taken to determine Hb, haematocrit,
platelet and white blood count.
In the group allocated to expectant management, i.e.
no RBC transfusion, it is allowed to give a patient ‘res-
cue’ RBC transfusion if this is clinically indicated. The
indications to give ‘rescue’ RBC transfusion are second-
ary PPH, resulting in hemodynamic instability or an Hb
value < 3.0 mmol/L (4.8 g/dL), serious physical com-
plaints or other serious general complications. Possible
serious physical complaints are: dyspnoea, syncope,
orthostatic complaints, tachycardia (>100 bpm), myocar-
dial ischemia or transient ischemic attacks (TIA).
Additional use of medication to treat anaemia, like
oral and parenteral iron medication and other types of
medication, is allowed in both groups and may be pre-
scribed according to local protocol. Type and duration
of the use of this medication will be recorded.
Outcome
Primary outcome is physical fatigue on day three
postpartum, scored with a dimension of the HRQoL
m e a s u r eM F I .W ea i mt os h o wn o n - i n f e r i o r i t yo ft h e
expectant management arm and therefore this pri-
mary assessment day was chosen: if there would be
any difference between randomized groups, this dif-
ference is expected to be the largest three days post-
partum [5]. In total three measures of HRQoL will be
scored. Secondary outcomes will be the remaining
HRQoL measures and the number of RBC transfu-
sions. In addition an anaemia related symptoms list
will be filled in before randomisation and at six weeks
postpartum.
Medical process parameters to be evaluated include
the increase of Hb level after RBC transfusion and
acute transfusion complications. Moreover, we will
compare the length of hospital stay and serious physi-
cal complications during the first six weeks postpartum
(infections, thromboembolic events, hemodynamic
events, cardiac events, neurologic events, secondary
HPP, obstetric interventions, ‘rescue’ RBC transfusion).
A costs benefit analysis will also be performed (see
‘Economic Evaluation’).
HRQoL questionnaires
HRQoL will be scored with three measures: the generic
measures Short Form-36 (SF-36) and EuroQol-5 D (EQ-
5D) and the fatigue specific measure MFI.
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vey with only 36 questions. It consists of 36 items, orga-
nized into eight scales: Physical Functioning, Role-
Physical, Bodily Pain, General Health, Vitality, Social
Functioning, Role-Emotional, and Mental Health. The
number of response choices per item ranges from two
to six. The SF-36 yields an eight-dimensional profile,
with each scale having a range from 0 to 100 (100 =
optimal). The SF-36 furthermore provides a physical
summary score and a mental summary score. The SF-36
has proven useful in surveys of general and specific
populations, comparing the relative burden of diseases,
and in differentiating the health benefits produced by a
wide range of different treatments [13,14].
The EQ-5 D is a standardised measure of health status
and provides a simple, generic measure of health for
clinical and economic appraisal. It consists of five items
(Mobility, Self-Care, Usual Activities, Pain/Discomfort,
and Anxiety/Depression), each following the general
form: 1 = no problems,2=some problems,3=extreme
problems. The sixth item is a global evaluation of own
health on a visual analogue scale (EQ-VAS) with a
range from 0 (worst imaginable health state)t o1 0 0
(best imaginable health state). Applicable to a wide
range of health conditions and treatments, it provides a
s i m p l ed e s c r i p t i v ep r o f i l ea n das i n g l ei n d e xv a l u ef o r
health status that can be used in the clinical and eco-
nomic evaluation of health care as well as in population
health surveys [15].
The MFI is a 20-item self-report instrument designed
to measure fatigue. It covers the following dimensions:
General Fatigue, Physical Fatigue, Mental Fatigue,
Reduced Motivation and Reduced Activity. Each dimen-
sion is covered by a five-item scale. The number of
response choices per item is four. Each scale has ranges
from 4 to 20 (4 = optimal). The MFI was developed as a
tool to assess fatigue in a comprehensive way, with a
special interest in fatigue as experienced by patients and
provides information on the nature of the experience,
and its intensity [16].
The international standard HRQoL measures MFI,
EQ-5 D, and SF-36 have been evaluated in a pilot study;
feasibility, reliability, and validity of these measures in a
clinical obstetric setting were established [5].
Follow-up
The follow-up period consists of six weeks. At fixed
moments during this period (at inclusion, three days,
one, three and six weeks) HRQoL questionnaires will
completed. The EQ-5 D and MFI will be filled in at all
these fixed moments while the SF-36 will be used one,
three and six weeks postpartum.
Details of the delivery, RBC transfusion (when given)
and follow-up are recorded in the CRF. During the
study period all transfusion complications will be
recorded. An anaemia related symptoms list is filled in
before randomisation and at six weeks postpartum. Hb
values will be determined at inclusion and six weeks
postpartum. Six weeks postpartum patients visit the out-
patient clinic.
In case of severe adverse events (SAE) during follow-
up, a SAE form will be downloaded from the website
and completed. SAE forms will be judged and based on
this conclusion the study will be discontinued if partici-
pation in the study is considered irresponsible.
Patients that withhold informed consent for randomi-
sation will be asked to complete the questionnaires, and
case record forms (CRF) will be recorded in a similar
way as patients that were randomised.
Statistics
Sample size
The HRQoL assessments were tested in postpartum
women in a pilot study [5]. For the comparison
between RBC transfusion and an expectant manage-
m e n tas a m p l es i z eo f4 0 0p a t i e n t si sp l a n n e d
(200 patients in the RBC transfusion group and 200
patients in the expectant management group). Power
calculations showed that with these numbers a differ-
ence of 1.3 points or greater in favour of the RBC arm
regarding the physical fatigue subscale on day three,
the primary outcome, can be excluded with a power of
80% at one-sided alpha of 0.025 assuming that there is
no difference on this day [5]. In view of the scale of
physical fatigue (ranging from 4 to 20) we think that
such a difference is not clinically relevant. Since miss-
i n gd a t aa r en o te x p e c t e dt oe x c e e d2 0 % ,at o t a lo f
500 patients will be included.
Data analysis
Data will be analysed according to the intention to treat
principle. The primary outcome, the MFI physical fati-
gue score at three days postpartum, will be compared
between groups using Repeated Measurement ANOVA.
This analysis allows for occasional missing values and
will be done using an unstructured covariance matrix,
while taking account of baseline value (at t = 0) and
mode of delivery as covariates. If the two-sided 95%
confidence interval for the adjusted difference of means
at day three excludes a difference of 1.3 points or
greater in favour of the RBC arm, non-inferiority of the
expectant policy is considered to be shown [17]. A per-
protocol analysis, including only patients without severe
protocol violations, will also be performed.
The mean profiles along time of other MFI subscales,
SF-36 and EQ-5 D will be compared similarly to the pri-
mary outcome measure. The other secondary outcome
measures will be assessed by calculating rates in groups,
risk differences and 95% confidence interval.
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T h ea i mo ft h ee c o n o m i ce v a l u a t i o ni st oc o m p a r et h e
costs and health effects of RBC transfusion versus
expectant management in women with acute anaemia
after PPH. As the clinical study is designed as an
equivalence study, the primary economic evaluation is a
cost-minimisation analysis. If RBC transfusion is shown
to improve the quality of life, the economic analysis will
be a cost-effectiveness analysis (time horizon: six weeks
postpartum). The analysis will be performed from a hos-
pital perspective. We will calculate direct costs (days in
hospital, number of RBC transfusions and costs of com-
plications). Real medical costs will be calculated by mul-
tiplying the volumes of health care use with the
corresponding cost prices. Unit costs of health care con-
sumption will be estimated according to national guide-
lines. Data on the volume of care will be available from
hospital information systems in the participating
hospitals.
Univariate analyses will be used for the analysis of
economic outcome data. We will use non-parametric
methods to test for differences between treatment
groups.
Ethical considerations
This study has been approved by the ethics committee
of the Erasmus Medical Centre Rotterdam (Ref. No.
MEC-2003-247) and by the management of all partici-
pating hospitals.
Discussion
Yearly, almost 200.000 women deliver in the Nether-
lands [18]. The number of women that receive one or
more RBC transfusions postpartum is estimated less
than 1% after vaginal delivery and between 1% and 7%
following caesarean section [3]. The present study may
lead to transfusion guidelines that are not only based on
Hb levels and/or clinical symptoms but also on HRQoL
measures. This may lead to a more judicious use of
RBC transfusions.
T oo u rk n o w l e d g e ,t h i si st h ef i r s ts t u d yi n v e s t i g a t i n g
worldwide the effect of RBC transfusion on postpartum
HRQoL in women with acute anaemia due to PPH.
A pilot study investigating the relation between postpar-
tum Hb levels and HRQoL measures during the first six
weeks postpartum, which is discussed below, was pub-
lished by our group in 2007 [19].
Several national health organisations have tried to
define transfusion triggers [20-24]. General consensus of
these guidelines is that RBC transfusion above 6 mmol/L
(9.7 g/dL) is not very useful, RBC transfusion below
4 mmol/L (6.4 g/dL) is probably useful, but with an Hb
value between 4 and 6 mmol/L individual characteristics
have to be taken in consideration for the decision to give
RBC transfusion. In the Netherlands, the Dutch “4-5-6
flexinorm” is empirically based and is intended for use in
the treatment of acute and chronic cases of anaemia [9].
However, considering the physiologic hemodynamic
changes during pregnancy and the postpartum period in
obstetric patients, the guideline might not be applicable
for this specific patient group.
The hypothesis of the present study is that HRQoL is
not or only to a small extent influenced by treatment
with RBC transfusion in this group of patients. The
results of our previous pilot study showed no correlation
between postpartum Hb levels and HRQoL after the
first week postpartum. The health effects of this study
will be the direct reduction of RBC transfusions, which
will result in a decrease of RBC transfusion-related com-
plications (formation of RBC alloantibodies, transfusion
complications and infectious complications) and days in
hospital. Another possible finding of this study may be
the definition of the desired Hb value after RBC
transfusion.
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